India is known as the “Pharmacy of the World” for its low-cost generic medicines, but a quieter revolution is underway in a different category: biosimilars. These are near-copies of complex biological drugs, and Indian manufacturers are rapidly winning approval from the Central Drugs Standard Control Organisation (CDSCO) to bring them to market. For international healthcare buyers and distributors, understanding how Indian biosimilars are approved and verified is increasingly important, because biotech medicines are where the next wave of affordable treatment options will come from.
🧬 What Is a Biosimilar — and How Is It Different From a Generic?
A generic is an exact chemical copy of a small-molecule drug (like paracetamol or amoxicillin) whose active compound can be reproduced precisely. A biosimilar is a copy of a biologic — a large, complex protein made inside living cells (e.g., antibodies, hormones, enzymes). Because biologics are made by living organisms, they cannot be copied molecule-for-molecule the way a chemical drug can.
Instead, a biosimilar must be shown to be highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. This is why biosimilar approval involves far more rigorous comparative testing than standard generic approval — a point that matters for buyers evaluating Indian producers.
- Generic = chemically identical copy of a small-molecule drug.
- Biosimilar = biologically similar copy of a large-molecule biologic drug.
- Reference biologic = the original branded biologic product the biosimilar is compared to.
🏛️ How CDSCO Regulates Biosimilars in India
In India, biosimilars are officially called “similar biologics.” CDSCO regulates them through the Drugs and Cosmetics Act, 1940, and the rules made thereunder, following the “Similar Biologics” Guidelines issued in 2012 and subsequently updated. Unlike generic small-molecule drugs, similar biologics must pass a phased comparability pathway that includes:
- Physicochemical and biological characterisation — proving structural and functional similarity to the reference biologic.
- Non-clinical (animal) studies — evidence of safety and biological activity where required.
- Clinical studies — comparative pharmacokinetic (PK)/pharmacodynamic (PD) data in patients for biologics where this is mandatory.
- GMP/GDP compliance — manufacturing and distribution controls, plus batch-to-batch consistency.
The exact requirements depend on the risk class of the biologic being copied. Permission for biosimilar clinical trials and manufacturing is issued by the CDSCO subjects to review by its Subject Expert Committees (SECs), who evaluate the comparability data before granting market approval.
⚡ New Biosimilar Guidelines in 2026 Ease Study Norms
2026 has been a defining year for Indian biosimilar regulation. According to ET Pharma (April 2026), the Drugs Controller General of India (DCGI) announced new biosimilar guidelines to ease bioequivalence study norms, streamlining the pathway for manufacturers to demonstrate similarity. This is intended to accelerate affordable biosimilar entry while maintaining safety oversight. [CITATION NEEDED] for the specific technical details of the eased norms.
The momentum reflects a broader push. As BioSpectrum India (January 2026) reported, India is positioning itself to “transition to a strategic global hub” for biosimilars, with local producers scaling biologics manufacturing for both domestic and export markets. [CITATION NEEDED] for specific production capacity figures.
📊 Why Indian Biosimilars Matter: 60–80% Savings
The cost advantage is the headline story. According to BioSpectrum India (January 2026), biosimilars in India are typically priced 60–80% lower than originator biologics, significantly improving access to costly therapies for cancer, autoimmune disease, diabetes, and other conditions.
Recent approvals illustrate the pace of growth:
- May 2026 — CDSCO approved Aurobindo’s CuraTeQ bevacizumab biosimilar (Bevqolva) for cancer treatment, targeting a reported ₹350 crore oncology market (Medical Dialogues).
- May 2026 — Dr. Reddy’s launched an oral semaglutide biosimilar in India for type 2 diabetes (as reported by Business Standard).
- August 2026 — Dr. Reddy’s won US FDA approval for a rituximab biosimilar, underscoring the export potential of Indian biologic developers.
These point to the rapid maturation of India’s biologics pipeline, from oncology blockbusters to metabolic treatments.
🔬 How to Assess the Quality of a Biosimilar
For buyers, the quality of a biosimilar is determined by the strength of its comparability package and the robustness of the manufacturer’s biologics manufacturing facility. Key checkpoints:
- Licensed/biologic license — confirm the product received CDSCO market approval for the specific reference biologic.
- Manufacturing site compliant — verify WHO-GMP / Schedule M compliance for biologics manufacturing (which requires separate cell-culture, cloning, and filling facilities).
- Clinical data — presence of a licensed clinical comparability study for the indication.
- Batch consistency — robust lot-release and stability data.
- Storage and cold chain — biologics are temperature-sensitive; verify cold-chain handling throughout transit.
Because biologics cannot be verified by simple tablet inspection, buyers should prioritize documented regulatory evidence and reputable sourcing over price alone.
🌐 How to Source Biosimilars Safely as an International Buyer
Cross-border procurement of biologics adds cold-chain complexity and regulatory tolerance. To minimize risk, work with verified distributors that can provide documentation and regulatory transparency. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
Always request, at minimum: the manufacturing license, the CDSCO approval letter, the WHO-GMP or export certificate, and a cold-chain validated batch release for every consignment. Never accept a biosimilar without verifiable documentation.
⚠️ Common Pitfalls When Buying Biosimilars
- Treating biosimilars like generics — they are not interchangeable without clinical justification and are far more sensitive to manufacturing/storage.
- Ignoring the cold chain — a single temperature breach can destroy a biologic without visible signs.
- Choosing from price alone — verify the regulatory approval and the manufacturing site, not just the invoice.
- Missing regulatory authorization — confirm the specific reference biologic and indication are approved.
✅ Buyer’s Quick Checklist
- ✅ Confirm the product is a CDSCO-approved similar biologic (not an unapproved copy).
- ✅ Verify the reference biologic originator it is compared against.
- ✅ Request the manufacturer’s CDSCO approval letter and license.
- ✅ Check WHO-GMP certification and cold-chain handling standards.
- ✅ Ask for batch-specific release and stability/consistency data.
- ✅ Ask that the distributor has documented regulatory compliance.
- ✅ Source through a verified distributor (see IMSDA directory).
- ✅ Plan a fully temperature-logged cold chain for transit.
❓ Frequently Asked Questions About Indian Biosimilars
Is a biosimilar the same as a generic drug?
No. A generic is chemically identical to a small-molecule drug and proven bioequivalent through a simple test. A biosimilar is highly similar to a large biologic molecule but requires far more extensive analytical and clinical comparability data.
Are Indian biosimilars safe?
When CDSCO-approved and made by a GMP-compliant manufacturer, Indian biosimilars meet the comparability and clinical standards set by the regulator. Safety and quality vary by manufacturer, so always verify regulatory approval and documentation.
Are biosimilar prices really lower in India?
Yes. According to BioSpectrum India (January 2026), biosimilars in India are typically 60–80% cheaper than originator biologics, which is why they are of great interest to global buyers.
🤝 Final Thoughts
India’s biosimilar sector is entering a defining growth phase. With eased 2026 guidelines, a growing pipeline of oncology and metabolic products, and price points 60–80% below originators, these therapies represent one of the most important opportunities for affordable care in the coming decade.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.